With the headlines focused on COVID-19, many may have forgotten about the escalating epidemic of substance use disorder. National Recovery Month is a time to bring this issue back to the top of the agenda, raise awareness, and drive action, writes Richard Pops, CEO of Alkermes.
The COVID-19 pandemic has exposed global health inequities and is driving life sciences companies to establish strategies and better leverage data to address systemic causes and improve equity in access to healthcare innovations, particularly in clinical trials.
Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.
Each program strengthens the pharma value chain, impacting the core areas of clinical development, supply chain, and manufacturing and commercial engagement.
In an unpredictable world, international life sciences collaborations can lead to misunderstandings and enforcement challenges, making an effective dispute resolution mechanism an essential risk management tool.
Current industry challenges present an opportunity for innovation and the adoption of new solutions, particularly in addressing barriers related to patient recruitment, engagement, and retention.
Strategies that can help maintain and grow your market share. Plus how to adapt to new competitive pressures and evolving customer needs.
As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Deployments are often built on the concept that growth comes from new prescribers, which may be limiting their success.
Mitigating the risks of development, authorization, and marketing for new therapies following "new normal" created by COVID-related violations.
Improving the patient experience for those with orphan diseases through a patient-first approach.
While COVID-driven challenges remain many, so do the carryover opportunities to redefine HCP engagement and communication.
The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
COVID-19 pandemic has accelerated raised expectations for medical information professionals.
How life sciences companies can design an effective operating model for DOL engagements.
***Live: Thursday, February 25, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET*** As strategic planning among manufacturers and logistics partners commences, this webinar will serve as a platform to discuss service offerings and explore the most effective possible solutions. *** On demand until Feb. 25, 2022***
To effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.
Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Integrating DEI strategies into clinical trials is both crucial for advancing biomedical knowledge and for bolstering trust and equitability within underrepresented communities.
Three simple ways to build trust—by reaching outside your comfort zone.
In order to address data literacy gaps amongst reps and managers, sales trainers are increasingly turning to computer-based business simulation games, writes Jeremy Lovelace.
We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.
Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.
Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Going beyond traditional market segmentation to understand the technological and data analytics capacity of target customers.
Opportunity remains despite regulatory and access obstacles.